Heart failure: Promising data for serelaxin

Abstract

Intriguing findings from the RELAX-AHF trial of serelaxin (recombinant human relaxin 2; RLX030, Novartis, Basel, Switzerland) in patients with acute heart failure were presented by John Teerlink at the 2012 AHA Scientific Sessions and published in the Lancet. Patients hospitalized with acute heart failure commonly have a dismal prognosis. Despite decades of… (More)
DOI: 10.1038/nrcardio.2012.174

Topics

  • Presentations referencing similar topics